ClinicalTrials.Veeva

Menu

A Study to Evaluate Clinical Benefit, Performance and Safety of Cochlear Implants in Adults (ORBIT-MU)

Cochlear logo

Cochlear

Status

Begins enrollment in 1 month

Conditions

Hearing Implants
Hearing Loss

Treatments

Device: Cochlear Nucleus Nexa Cochlear implant (CI1032)
Device: Cochlear Nucleus Nexa Cochlear implant (CI1022)
Device: Cochlear Nucleus Nexa Cochlear implant (CI1012)

Study type

Observational

Funder types

Industry

Identifiers

NCT07338864
CLTD5819

Details and patient eligibility

About

The aim of this clinical investigation is to demonstrate the performance, clinical benefit and safety of commercial cochlear implant systems. Speech performance and subjective hearing results, and comparison with cochlear implant results available in literature, is intended to demonstrate the performance and clinical benefit of the cochlear implant systems investigated in this study.

Enrollment

66 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18 years or older (at time of consent).
  • Clinically established post-linguistic moderately severe to profound sensorineural hearing loss, in the ear to be implanted.
  • Compromised functional hearing with hearing aid(s) or unlikely to receive benefit with hearing aid(s) in the ear to be implanted.
  • Cochlear implant candidate as determined by the Principal Investigator. Meets local candidacy criteria for cochlear implantation.
  • Candidate is a fluent speaker in the language used to assess speech perception performance.
  • Willing and able to comply with study follow-up schedule.
  • Willing and able to provide written informed consent.
  • Candidate has access to a Smartphone compatible with Nucleus Smart App.

Exclusion criteria

  • Prior cochlear implantation in the ear to be implanted.
  • Unrealistic expectations regarding the possible benefit, risks and limitations that are inherent to the surgical procedure and prosthetic device as determined by the investigator.
  • Any contraindications for cochlear implantation listed in the relevant product physician's guide (to be specified per sub-investigation).
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
  • Women who are pregnant.
  • Current participation, or participation in an interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).

Trial design

66 participants in 3 patient groups

Cochlear implant (CI1032)
Description:
Participants implanted with a CI1032
Treatment:
Device: Cochlear Nucleus Nexa Cochlear implant (CI1032)
Cochlear implant (CI1022)
Description:
Participants implanted with a CI1022
Treatment:
Device: Cochlear Nucleus Nexa Cochlear implant (CI1022)
Cochlear implant (CI1012)
Description:
Participants implanted with a CI1012
Treatment:
Device: Cochlear Nucleus Nexa Cochlear implant (CI1012)

Trial contacts and locations

1

Loading...

Central trial contact

cltd-prs-admin@cochlear.com PRS Specialist

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems